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ABSTRACT
The in-vitro activities of penicillin, ticarcillin–clavulanic acid, cefoxitin, imipenem, ertapenem,
metronidazole and clindamycin were evaluated against 138 Gram-negative anaerobic isolates (82
Bacteroides fragilis group, 17 non-fragilis Bacteroides spp., 31 Prevotella spp., four Fusobacterium spp., two
Veillonella spp., one Porphyromonas sp. and one Tissierella praeacuta) collected from six general hospitals
in Athens, Greece. Overall rates of non-susceptibility (both resistant and intermediately-resistant) to
penicillin and ticarcillin–clavulanic acid were 81.8% and 2.3%, respectively. The rates of non-
susceptibility to cefoxitin and clindamycin were 30.3% and 31.1%, respectively, and that for
metronidazole was 4.3% (four Prevotella spp. isolates, one Porphyromonas sp. isolate and one B. fragilis
isolate). Only the single B. fragilis isolate was nim-positive by PCR. Only one B. fragilis isolate was
resistant to both carbapenems tested, while six more Bacteroides spp. isolates were imipenem-susceptible
and ertapenem-non-susceptible. The MIC range, MIC50 and MIC90 values were comparable for
imipenem and ertapenem, although ertapenem MIC90s were one or two two-fold dilutions higher.
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INTRODUCTION
Anaerobic bacteria play a signiﬁcant role in mixed
aerobic–anaerobic infections such as intra-abdom-
inal, pelvic, obstetric–gynaecological and diabetic
foot infections [1]. Nevertheless, susceptibility
testing of clinical isolates is not considered man-
datory in routine clinical practice because of the
cost and complexity of the methods used, the
belief that resistance patterns of anaerobic bac-
teria are somewhat predictable, and the apparent
success of recommended antibiotic regimens [1,2].
Empirical antimicrobial chemotherapy is based
mainly on data obtained from multicentre epide-
miological studies. However, major variations
have been reported in recent years regarding the
in-vitro susceptibility of anaerobes in different
geographical regions [2], with increased resist-
ance in some areas. Therefore, periodic surveil-
lance of the activity of the most widely used
antimicrobial agents is now considered useful [1].
In Greece, few hospitals perform susceptibility
testing. Therefore, data are scarce [3,4] and a
surveillance system does not exist. In addition,
resistance rates among aerobic bacteria are
high, especially among nosocomial pathogens
(as reported also by the European Anti-
microbial Resistance Surveillance System;
http://www.earss.rivm.nl), a fact that has been
attributed mainly to the extensive use of newer
antimicrobial agents in empirical chemotherapy.
Thus, a study group was formed to collate
susceptibility results in Greece and to study
the respective mechanisms of resistance. This
study presents the ﬁrst available data from this
group.
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MATERIALS AND METHODS
Clinical isolates were collected consecutively from documen-
ted infections during the period December 2002 to January
2004 from six general hospitals (ﬁve hospitals with adult
patients and one paediatric hospital) in Athens, with c. 3000
beds in total. Processing of clinical specimens and culture,
bacterial isolation and level I, II and III identiﬁcation were
performed according to standard methodology [1], supple-
mented by the Rapid ID32 A system (bioMe´rieux, Marcy
l’Etoile, France) and ⁄ or the BBL Crystal Anaerobe ID system
(Becton Dickinson, Sparks, MD, USA) in the hospital laborat-
ories. Subsequently, all isolates were collected at a single
laboratory (Laikon General Hospital), where species identiﬁ-
cation was completed and antimicrobial susceptibility testing
was performed. Isolates were stored at )70C in sterilised
skimmed milk.
Metronidazole susceptibility screening was performed with
a 5-lg disk as described previously [5]. MICs of benzylpen-
icillin, ticarcillin–clavulanic acid, cefoxitin, imipenem, ertape-
nem, metronidazole and clindamycin were determined by the
Etest method (AB Biodisk, Solna, Sweden) according to the
manufacturer’s instructions. Brieﬂy, a 1· McFarland turbidity
suspension in brucella broth was prepared from a 48-h culture
plate and then spread on to brucella agar plates supplemented
with horse blood 5% v ⁄v, vitamin K1 1 mg ⁄L and haemin
5 mg ⁄L [1]. Ertapenem Etest strips were kindly provided by
Vianex ⁄MSD (Nea Erithrea, Greece). The plates were incuba-
ted for 48 h in a Bactron 1.5 Anaerobic Chamber (Cheldon
Manufacturing, Cornelius, OR, USA) and examined after 24
and 48 h. The results were interpreted according to NCCLS
guidelines [6]. For ertapenem, breakpoints of £ 4 mg ⁄L (sus-
ceptible), 8 mg ⁄L (intermediate) and ‡ 16 mg ⁄L (resistant) [7]
were used.
b-Lactamase production was tested with nitrocephin disks
(Ceﬁnase; BBL, Becton Dickinson). Throughout the study, full
anaerobiosis was ensured with methylene blue strips and
resazurin. Bacteroides fragilis ATCC 25285 and Bacteroides
thetaiotaomicron ATCC 29741 were used for susceptibility
testing quality control, and all tests providing metronidazole-
non-susceptible results were repeated.
DNAwas extracted from 48-h cultures of all metronidazole-
non-susceptible isolates with a QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany), used according to the manufac-
turer’s instructions. PCR detection of nim genes, which
confer resistance to metronidazole, was performed with the
nim3 ⁄nim5 primer set as described previously [8], using a
PTC-200 Thermal Cycler (MJ Research, Watertown, MA, USA).
PCR products were analysed by electrophoresis in agarose
1.5% w ⁄v gels, followed by staining with ethidium bromide
and visualisation under UV illumination.
RESULTS
During the study period, 138 consecutive Gram-
negative anaerobic bacterial isolates were
obtained from the participating microbiology
departments. Clinical specimens included blood,
and samples from intra-abdominal, pelvic, soft
tissue and diabetic foot infections. In total, 82
(59%) isolates belonged to the B. fragilis group,
and 17 were identiﬁed as non-fragilis Bacteroides
spp. Other isolates were identiﬁed as Prevotella
spp. (n = 31), Fusobacterium spp. (n = 4), Veillonella
spp. (n = 2), Porphyromonas spp. (n = 1) and Tis-
sierella praeacuta (n = 1) (Table 1).
MIC ranges, MIC50 and MIC90 values, and the
percentage of resistant, intermediately-resistant
and susceptible isolates belonging to the major
groups of bacteria are presented in Table 2 for
each antimicrobial agent. Overall, the rate of non-
susceptibility (both resistant and intermediately-
resistant) to benzylpenicillin was 81.8%, largely
because of the predominance of Bacteroides spp.,
while Prevotella spp. isolates were less resistant
(62.1%). All penicillin-resistant isolates were
b-lactamase-positive. In contrast, ticarcillin–
clavulanic acid was highly effective, with only
2.3% non-susceptible isolates, all of which be-
longed to the B. fragilis group. High rates of
intermediate resistance and resistance to cefoxitin,
as well as clindamycin resistance, were recorded.
Carbapenem resistance was detected only among
Bacteroides spp. One B. fragilis isolate was resistant
to both imipenem and ertapenem, and was also
resistant to all other antibiotics tested except
metronidazole. In addition, two B. fragilis isolates,
one Bacteriodes ovatus isolate and one Bacteriodes
capillosus isolate were imipenem-susceptible and
Table 1. Genus and species distribution of the isolates
Genus and species No.
Bacteroides fragilis group 82
B. fragilis 40
B. thetaiotaomicron 14
B. uniformis 8
B. ovatus 6
B. merdae 4
B. vulgatus 3
B. distasonis 4
B. eggerthii 2
B. caccae 1
Non-fragilis Bacteroides spp. 17
B. capillosus 13
B. ureolyticus 4
Prevotella spp. 31
P. oralis 9
P. bivia 7
P. buccalis 3
P. loescheii 3
P. buccae 3
P. disiens 2
P. intermedia 2
P. denticola 1
P. melaninogenica 1
Fusobacterium spp. 4
F. nucleatum 2
F. russii 1
F. varium 1
Veillonella spp. 2
Tissierella praeacuta 1
Porphyromonas spp. 1
Total Gram-negative anaerobes 138
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ertapenem-resistant, while two B. fragilis isolates
were imipenem-susceptible, but intermediately-
resistant to ertapenem. The MIC distributions for
both agents were comparable, although ertape-
nem MICs in general were slightly higher and the
MIC50 and the MIC90 values of the two com-
pounds differed by one or two two-fold dilutions
(Table 2).
Resistance to metronidazole was detected in six
(4.3%) isolates, comprising three Prevotella oralis
(MIC > 256 mg ⁄L for all three), one Prevotella
buccalis (MIC > 256 mg ⁄L), one Porphyromonas sp.
(MIC > 256 mg ⁄L) and one B. fragilis (MIC
16 mg ⁄L). With use of the 5-lg metronidazole
disk, all six isolates had zone diameters ranging
from 0 to 8 mm. Susceptibility testing for met-
ronidazole for all six isolates was repeated using
the disk protocol and the Etest method, and no
discrepancies were detected. Only the single
resistant B. fragilis isolate was found to be positive
for nim genes by PCR.
DISCUSSION
As expected, a high rate of resistance to benzyl-
penicillin was recorded, mainly among Bacteroides
spp. [9]. Bacteroides spp. usually produce b-lacta-
mases that confer resistance to penicillin, a fact
conﬁrmed in this study by the nitrocephin disk
method. The MIC range distribution of cefoxitin
was near the intermediately-resistant breakpoint
(MIC50 8 mg ⁄L), as described previously [10].
Considering its usefulness in empirical chemo-
therapy, closer surveillance of cefoxitin suscepti-
bility may be worthwhile in the near future.
Ticarcillin–clavulanic acid was highly active
against almost all the isolates tested.
A single B. fragilis isolate was highly resistant to
both carbapenems tested, while six (4.3%) imipe-
nem-susceptible isolates were found to be non-
susceptible to ertapenem. A previous study,
which tested whether imipenem can be used as
a surrogate agent for predicting susceptibility to
Table 2. MIC range, MIC50 and MIC90 values, and percentages of resistant, intermediately-resistant and susceptible
isolates for each antimicrobial agent tested
Antimicrobial agent and organism No.tested
MIC (mg ⁄L) % of MIC
Range MIC50 MIC90 R I S
Benzylpenicillin
Total Gram-negative 138 0.016 to > 256 32 256 78.0 3.8 18.2
B. fragilis group 82 0.125 to > 256 32 256 89.8 3.8 6.4
Non-fragilis Bacteroides spp. 17 0.032 to > 256 64 256 87.5 0 12.5
Prevotella spp. 31 0.016 to > 256 2 128 58.7 3.4 37.9
Ticarcillin–clavulanic acid
Total Gram-negative 138 0.016 to > 256 0.125 2 1.5 0.8 97.7
B. fragilis group 82 0.016–256 0.125 4 2.6 1.3 96.1
Non-fragilis Bacteroides spp. 17 0.016 – 16 0.125 1 0 0 100.0
Prevotella spp. 31 0.016–2 0.016 0.5 0 0 100.0
Cefoxitin
Total Gram-negative 138 0.016 to > 256 8 64 10.6 19.7 69.7
B. fragilis group 82 0.125 to > 256 16 128 16.7 21.8 61.5
Non-fragilis Bacteroides spp. 17 0.25–128 16 32 6.3 43.8 49.9
Prevotella spp. 31 0.032–32 1 16 0 6.9 93.1
Imipenem
Total Gram-negative 138 0.008–32 0.125 0.5 0.8 0 99.2
B. fragilis group 82 0.008–32 0.125 1 1.3 0 98.7
Non-fragilis Bacteroides spp. 17 0.016–1 0.125 0.5 0 0 100.0
Prevotella spp. 31 0.016–0.25 0.064 0.125 0 0 100.0
Ertapenem
Total Gram-negative 138 0.004 to > 32 0.25 1 3.8 1.5 94.7
B. fragilis group 82 0.064 to > 32 0.25 4 5.1 2.6 92.3
Non-fragilis Bacteroides spp. 17 0.004–16 0.25 1 6.3 0 93.7
Prevotella spp. 31 0.008–1 0.125 0.5 0 0 100.0
Metronidazole
Total Gram-negative 138 0.016 to > 256 0.5 2 4.3 0 95.7
B. fragilis group 82 0.125–16 0.5 1 0 1.3 98.7
Non-fragilis Bacteroides spp. 17 0.032–8 0.5 1 0 0 100.0
Prevotella spp. 31 0.016 to > 256 0.5 256 12.9 0 87.1
Clindamycin
Total Gram-negative 138 0.016 to > 256 1 256 25.8 5.3 68.9
B. fragilis group 82 0.016 to > 256 1 256 23.1 7.7 69.2
Non-fragilis Bacteroides spp. 17 0.032–256 1 32 31.3 0 68.7
Prevotella spp. 31 0.032 to > 256 64 256 27.6 3.4 69.0
Data are shown accumulated as total Gram-negative bacteria, as well as for the three major groups of isolates (Bacteroides fragilis group, non-fragilis Bacteroides spp., and
Prevotella spp.).
R, resistant; I, intermediately-resistant; S, susceptible.
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ertapenem [11], found that 98.6% of imipen-
em-susceptible strains were also susceptible to
ertapenem. The higher rate of discrepancies
detected in the present study warrants further
investigation, although imipenem is still consid-
ered to be particularly active against anaerobes
in vitro. Imipenem resistance among anaerobes is
usually mediated by a zinc-dependent metallo-
b-lactamase encoded by the cﬁA gene. It has been
shown that imipenem-susceptible and -resistant
strains may carry this gene, although resistant
strains also carry an insertion sequence that
probably triggers gene expression [2].
Major geographical differences in carbapenem
resistance have been described previously, inclu-
ding differences between and within countries,
and even between hospitals in the same area
[2,12]. Imipenem and ertapenem MIC90 values for
the B. fragilis group isolates in the present study
(1 and 4 mg ⁄L, respectively) were comparable
with those reported in a major European–Austra-
lian study (0.5 and 2 mg ⁄L, respectively) [13], but
higher than those reported in two major USA
studies (0.25 and 1 mg ⁄L, and 0.5 and 1 mg ⁄L,
respectively) [14,15]. It seems that isolates from
Europe are, in general, less susceptible to carbap-
enems than isolates from the USA. However, the
one or two two-fold dilution difference in
the MIC90 values for the two compounds was
the same in all studies; thus, compared with
ertapenem, imipenem appears to be slightly more
active against Gram-negative anaerobic bacteria.
Nevertheless, the MIC90 values of both com-
pounds are well within the susceptible range,
making them an excellent choice for treatment of
mixed intra-abdominal infections.
Six (4.3%) isolates were metronidazole-non-
susceptible. Taking into account that no resistance
has been detected previously in Greece [3,4], the
present situation is considered to be a novel and
major clinical challenge, and may be attributed to
the extensive local use of metronidazole in empir-
ical chemotherapy. Metronidazole resistance rates
of 0–1% have been reported among anaerobic
bacteria [2,9,14,16], although resistance of £ 7%
has also been reported [17]. In addition, a 2.8%
rate of reduced susceptibility (MIC 4–8 mg ⁄L)
was reported by the ESCMID Study Group on
Antimicrobial Resistance of Anaerobic Bacteria
(ESGARAB) [2], which corresponds with the
results of the present study, in which four isolates
had MICs of 4 and 8 mg ⁄L.
Isolates with metronidazole MICs as low as
0.5 mg ⁄L may carry resistance genes of the nim
class [2,5], and it has been suggested that the
NCCLS breakpoint of 32 mg ⁄L may conceal such
low-level resistance [2]. Nevertheless, the true
clinical signiﬁcance of this type of resistance is
unknown, as therapeutic failures have not been
described. The present study detected nim genes
only in a single B. fragilis isolate. The PCR
protocol used has been evaluated extensively
among isolates of Bacteroides spp. [5,8], although
other versions have been used with different
species, but with discrepant results [18], as
metronidazole-resistant isolates have been found
negative by all other methods. Further work is
being performed to investigate the nature of
resistance in the remaining isolates, as mecha-
nisms apart from the nim genes have also been
reported [5,19].
The clindamycin resistance rate was 23.1%
among isolates belonging to the B. fragilis group,
with a further 7.7% being intermediately-resistant;
this is higher than the rates of resistance (£ 15%)
reported previously in Greece [3] and higher than
the cumulative results from the ESCARAB study
[2], thereby conﬁrming the observation of higher
resistance rates in Mediterranean countries than
those in northern Europe [2,4]. Even higher resist-
ance rates (of up to 49%) have been reported in
studies from the USA, Spain and France [9,10,20],
indicating an increase in isolates carrying clinda-
mycin resistance determinants that are capable of
transfer between bacteria of the normal ﬂora [21].
Taking into account the fact that the high resist-
ance rate detected in the Spanish study [10] was in
isolates from faecal samples of healthy volunteers,
coupled with the endogenous origin of most
anaerobic infections, it may be time to reconsider
the extensive use of clindamycin for empirical
treatment of mixed aerobic–anaerobic infections or
surgical prophylaxis.
In conclusion, according to the ﬁrst multicentre
results from Greece, b-lactam–inhibitor combina-
tions, carbapenems and metronidazole have high
in-vitro efﬁcacy against Gram-negative anaerobes,
although the evidence that metronidazole resist-
ance may be emerging requires closer surveil-
lance. The high rates of intermediate resistance
and resistance to cefoxitin and clindamycin detec-
ted in this study indicate that susceptibility
testing should be performed routinely. Continued
enhanced surveillance of resistance in anaerobic
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bacteria should help to avoid failures in empirical
antimicrobial chemotherapy and will enable
the timely modiﬁcation of chemoprophylaxis
protocols.
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